AARTIDRUGS

Aarti Drugs Limited

API and specialty chemicals for antibiotics and other therapeutic categories

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

aartidrugs.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹396.35
Market cap
3,622 Cr
Stock P/E
18.9
P/B
2.33
Dividend yield
0.5%
ROE (FY26)
12.6%
ROCE (FY26)
11.5%
Operating margin (FY26)
9.4%
Debt / equity (FY26)
0.37
OCF / EBITDA (FY26)
82.0%
OCF / EBITDA (3Y)
93.9%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Aarti Drugs makes active pharmaceutical ingredients (APIs, the bulk drug substances inside medicines) for antibiotic, antiprotozoal, anti-inflammatory, antidiabetic and antifungal medicines, and sells them to drug makers in India and in 100+ countries.

Company snapshot

66thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓94% of operating profit came in as cash over the last three years — profits are backed by real cash.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales642 Cr606 Cr620 Cr555 Cr598 Cr557 Cr677 Cr591 Cr653 Cr602 Cr720 Cr703 Cr
Operating expenses (approx.)565 Cr536 Cr534 Cr490 Cr531 Cr495 Cr583 Cr516 Cr569 Cr547 Cr625 Cr605 Cr
EBITDA76 Cr70 Cr86 Cr65 Cr67 Cr62 Cr93 Cr74 Cr84 Cr55 Cr96 Cr98 Cr
OPM %11.9%11.6%13.8%11.7%11.2%11.1%13.8%12.5%12.9%9.1%13.3%14.0%
Other income0.68 Cr2 Cr1 Cr1 Cr1 Cr12 Cr2 Cr0.31 Cr0.09 Cr1 Cr0.76 Cr0.81 Cr
Interest8 Cr8 Cr9 Cr9 Cr9 Cr9 Cr9 Cr9 Cr8 Cr9 Cr8 Cr9 Cr
Depreciation13 Cr13 Cr14 Cr13 Cr14 Cr14 Cr15 Cr15 Cr16 Cr18 Cr18 Cr18 Cr
Profit before tax56 Cr52 Cr64 Cr44 Cr46 Cr51 Cr71 Cr51 Cr60 Cr29 Cr70 Cr69 Cr
Tax %29.6%28.8%26.3%24.4%23.8%26.9%11.8%-5.6%25.2%-39.7%21.5%27.6%
Net profit40 Cr37 Cr47 Cr33 Cr35 Cr37 Cr63 Cr54 Cr45 Cr41 Cr55 Cr50 Cr
EPS (₹)₹4.29₹3.99₹5.15₹3.62₹3.83₹4.06₹6.88₹5.91₹4.95₹4.44₹6.05₹5.49

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,288 Cr1,263 Cr1,561 Cr1,806 Cr2,155 Cr2,489 Cr2,716 Cr2,529 Cr2,387 Cr2,565 CrSign in free for the trailing twelve months
Operating expenses (approx.)1,101 Cr1,064 Cr1,354 Cr1,544 Cr1,718 Cr2,159 Cr2,410 Cr2,212 Cr2,100 Cr2,256 CrSign in free for the trailing twelve months
EBITDA187 Cr198 Cr207 Cr262 Cr437 Cr329 Cr306 Cr316 Cr287 Cr309 CrSign in free for the trailing twelve months
OPM %14.5%15.7%13.3%14.5%20.3%13.2%11.3%12.5%12.0%12.1%Sign in free for the trailing twelve months
Other income4 Cr1 Cr6 Cr1 Cr5 Cr11 Cr2 Cr4 Cr16 Cr2 CrSign in free for the trailing twelve months
Interest36 Cr35 Cr40 Cr34 Cr23 Cr21 Cr33 Cr34 Cr36 Cr34 CrSign in free for the trailing twelve months
Depreciation38 Cr40 Cr43 Cr49 Cr50 Cr50 Cr50 Cr51 Cr56 Cr67 CrSign in free for the trailing twelve months
Profit before tax116 Cr125 Cr131 Cr185 Cr369 Cr270 Cr224 Cr236 Cr212 Cr211 CrSign in free for the trailing twelve months
Tax %29.5%33.9%31.5%23.7%24.0%24.1%25.8%27.1%20.6%7.6%Sign in free for the trailing twelve months
Net profit82 Cr82 Cr90 Cr141 Cr280 Cr205 Cr166 Cr172 Cr168 Cr195 CrSign in free for the trailing twelve months
EPS (₹)₹33.46₹34.41₹38.48₹60.57₹30.09₹22.12₹17.97₹18.56₹18.35₹21.36Sign in free for the trailing twelve months
Dividend payout %————8.3%4.6%5.7%5.4%5.4%9.3%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital24 Cr24 Cr24 Cr23 Cr93 Cr93 Cr93 Cr92 Cr91 Cr91 Cr
Reserves376 Cr432 Cr520 Cr629 Cr820 Cr944 Cr1,100 Cr1,190 Cr1,278 Cr1,458 Cr
Borrowings446 Cr508 Cr471 Cr338 Cr305 Cr538 Cr607 Cr562 Cr612 Cr575 Cr
Other liabilities345 Cr424 Cr448 Cr586 Cr548 Cr633 Cr622 Cr588 Cr593 Cr691 Cr
Total liabilities1,191 Cr1,388 Cr1,463 Cr1,577 Cr1,766 Cr2,208 Cr2,421 Cr2,432 Cr2,575 Cr2,815 Cr
Fixed assets (net)575 Cr598 Cr622 Cr642 Cr659 Cr686 Cr675 Cr808 Cr856 Cr1,068 Cr
CWIP14 Cr28 Cr33 Cr12 Cr19 Cr77 Cr210 Cr225 Cr330 Cr214 Cr
Investments12 Cr11 Cr12 Cr13 Cr23 Cr24 Cr19 Cr20 Cr22 Cr27 Cr
Loans & advances——0 Cr0 Cr0 Cr0 Cr0 Cr0.24 Cr0.76 Cr0.70 Cr
Inventories210 Cr278 Cr247 Cr325 Cr415 Cr526 Cr516 Cr486 Cr473 Cr491 Cr
Trade receivables297 Cr373 Cr459 Cr489 Cr555 Cr750 Cr865 Cr705 Cr751 Cr830 Cr
Cash & bank4 Cr4 Cr6 Cr8 Cr10 Cr22 Cr9 Cr7 Cr5 Cr7 Cr
Other assets79 Cr95 Cr85 Cr87 Cr84 Cr124 Cr127 Cr182 Cr136 Cr177 Cr
Total assets1,191 Cr1,388 Cr1,463 Cr1,577 Cr1,766 Cr2,208 Cr2,421 Cr2,432 Cr2,575 Cr2,815 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity175 Cr70 Cr143 Cr251 Cr155 Cr70 Cr134 Cr359 Cr245 Cr254 Cr
Cash from investing-107 Cr-74 Cr-62 Cr-33 Cr-72 Cr-149 Cr-164 Cr-224 Cr-165 Cr-173 Cr
Cash from financing-68 Cr4 Cr-80 Cr-215 Cr-81 Cr92 Cr17 Cr-136 Cr-82 Cr-77 Cr
Net cash flow-0.45 Cr0.15 Cr1 Cr2 Cr2 Cr13 Cr-13 Cr-0.76 Cr-2 Cr3 Cr
Free cash flow (OCF − Capex)66 Cr-5 Cr69 Cr203 Cr155 Cr-74 Cr-30 Cr133 Cr67 Cr80 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %18.0%16.5%16.8%22.1%32.2%18.5%14.3%14.6%12.5%11.5%
ROE %20.4%18.1%16.5%21.7%30.7%19.8%13.9%13.4%12.3%12.6%
Debtor days841081079994110116102115118
Inventory days10312790104124115106113120119
Days payable9711888105981029999105116
Cash conversion cycle9011710897119122123116129121
OCF / EBITDA %93.5%35.2%69.0%95.8%35.4%21.1%43.9%113.4%85.2%82.0%
OCF / EBITDA % (3 years)——65.4%69.4%60.5%46.2%33.5%59.1%81.1%93.9%
Debt / equity1.121.120.870.520.330.520.510.440.450.37
Current ratio1.161.191.331.441.781.481.601.661.601.59
Net debt / EBITDA2.37—2.251.260.671.571.961.762.121.84